 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | EGFR806-specific CAR T-cell therapy / Cellevolve Bio, Seattle Children's Therapeutics
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: STRIvE-01: EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov) - Apr 8, 2024
P1, N=44, Recruiting, Sponsor: Seattle Children's Hospital
Trial completion date: Jun 2038 --> Jun 2040 | Trial primary completion date: Jun 2024 --> Jun 2025
- | HER2-Specific CAR T / Cellevolve Bio, Seattle Children's Therapeutics
Enrollment closed, Enrollment change, CAR T-Cell Therapy, IO biomarker: HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors (clinicaltrials.gov) - Dec 19, 2023
P1, N=10, Active, not recruiting, Sponsor: Seattle Children's Hospital
Trial completion date: Jun 2038 --> Jun 2040 | Trial primary completion date: Jun 2024 --> Jun 2025 Recruiting --> Active, not recruiting | N=48 --> 10
- | EGFR806-specific CAR T-cell therapy / Cellevolve Bio, Seattle Children's Therapeutics
Trial primary completion date, CAR T-Cell Therapy: STRIvE-01: EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov) - Jul 17, 2023
P1, N=44, Recruiting, Sponsor: Seattle Children's Hospital
Recruiting --> Active, not recruiting | N=48 --> 10 Trial primary completion date: Jun 2023 --> Jun 2024
- | SCRI-CARB7H3(s)x19 / Seattle Children's Hospital, SCRI-CARB7H3(s) / Cellevolve Bio
Enrollment closed, CAR T-Cell Therapy, IO biomarker: STRIvE-02: B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov) - Jul 10, 2023
P1, N=68, Active, not recruiting, Sponsor: Seattle Children's Hospital
Trial primary completion date: Jun 2023 --> Jun 2024 Recruiting --> Active, not recruiting
- | EGFR806-specific CAR T-cell therapy / Cellevolve Bio, Seattle Children's Therapeutics
Enrollment open, CAR T-Cell Therapy: Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors (clinicaltrials.gov) - Jun 12, 2023
P1, N=72, Recruiting, Sponsor: Seattle Children's Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | EGFR806-specific CAR T-cell therapy / Cellevolve Bio, Seattle Children's Therapeutics
New P1 trial, CAR T-Cell Therapy: Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors (clinicaltrials.gov) - Mar 15, 2023
P1, N=72, Not yet recruiting, Sponsor: Seattle Children's Hospital
- CE-VST01-JC / Cellevolve Bio
Discussant: CE-VST01-JC: a Novel Allogeneic T-cell Based Immunotherapy for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2040;
- CE-VST01-JC / Cellevolve Bio
Presenter: CE-VST01-JC: a Novel Allogeneic T-cell Based Immunotherapy for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2039;
- | EGFR806-specific CAR T-cell therapy / Cellevolve Bio, Seattle Children's Therapeutics
Enrollment closed, Enrollment change, CAR T-Cell Therapy, IO biomarker: EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors (clinicaltrials.gov) - Jan 20, 2023
P1, N=11, Active, not recruiting, Sponsor: Seattle Children's Hospital
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=36 --> 11
- | depatuxizumab (ABT-806) / AbbVie, EGFR806-specific CAR T-cell therapy / Cellevolve Bio, Seattle Children's Therapeutics
Journal: EGFR as a potent CAR T target in triple negative breast cancer brain metastases. (Pubmed Central) - Nov 2, 2022
Our results demonstrates anti-tumor activity of EGFR806 CAR T cells against TNBC cells in vitro and in vivo. Given EGFR806 CAR T cells are currently undergoing clinical trials in primary brain tumor patients without obvious toxicity, our results are immediately actionable against the TNBC-BM patient population.
- | CE-VST01-JC / Cellevolve Bio
Trial completion date: ASCEND-JC: A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML (clinicaltrials.gov) - Oct 13, 2022
P2, N=60, Not yet recruiting, Sponsor: Cellevolve Bio Inc
Given EGFR806 CAR T cells are currently undergoing clinical trials in primary brain tumor patients without obvious toxicity, our results are immediately actionable against the TNBC-BM patient population. Trial completion date: Jul 2024 --> Apr 2025
- | CE-VST01-JC / Cellevolve Bio
New P2 trial: ASCEND-JC: A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML (clinicaltrials.gov) - Sep 15, 2022
P2, N=60, Not yet recruiting, Sponsor: Cellevolve Bio Inc
- SCRI-CARB7H3(s) / Cellevolve Bio, Seattle Children's Therapeutics
STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors. (Available On Demand; 226) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3833;
P1
CAR-T cell expansion and persistence may be necessary to achieve objective responses. STRIvE-02 Arm B will explore dual expression of CD19 CAR with B7H3 CAR, using lymphocytic CD19 expression to drive CAR expansion and persistence.
- EGFR806-specific CAR T-cell therapy / Cellevolve Bio, Seattle Children's Therapeutics
STRIvE-01: Phase I study of EGFR806 CAR T-cell immunotherapy for recurrent/refractory solid tumors in children and young adults. (Available On Demand; 196) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1601;
P1
EGFR806 directed CAR-T cells have an acceptable toxicity profile in CYA with R/RST and demonstrate anti-tumor activity in some patients. Additional analyses are ongoing to identify biomarkers of response and toxicity.
- | EGFR806-specific CAR T-cell therapy / Cellevolve Bio, Seattle Children's Therapeutics
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: STRIvE-01: EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov) - Apr 22, 2021
P1, N=36, Recruiting, Sponsor: Seattle Children's Hospital
Additional analyses are ongoing to identify biomarkers of response and toxicity. Trial completion date: Jun 2036 --> Jun 2038 | Trial primary completion date: Jun 2021 --> Jun 2023
- | HER2-Specific CAR T / Cellevolve Bio, Seattle Children's Therapeutics
Trial completion date, Trial primary completion date, CAR T-Cell Therapy, IO biomarker: HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors (clinicaltrials.gov) - Mar 15, 2021
P1, N=48, Recruiting, Sponsor: Seattle Children's Hospital
Trial completion date: Jun 2036 --> Jun 2038 | Trial primary completion date: Jun 2021 --> Jun 2023 Trial completion date: Jul 2036 --> Jul 2039 | Trial primary completion date: Jul 2021 --> Jul 2024
- | EGFR806-specific CAR T-cell therapy / Cellevolve Bio, Seattle Children's Therapeutics
Trial completion date, Trial primary completion date, CAR T-Cell Therapy, IO biomarker: EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors (clinicaltrials.gov) - Mar 15, 2021
P1, N=36, Recruiting, Sponsor: Seattle Children's Hospital
Trial completion date: Jul 2036 --> Jul 2039 | Trial primary completion date: Jul 2021 --> Jul 2024 Trial completion date: Mar 2037 --> Mar 2040 | Trial primary completion date: Mar 2022 --> Mar 2025
- depatuxizumab (ABT-806) / AbbVie, Life Science Pharma, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] High affinity chimeric antigen receptor with cross-reactivity to clinically-relevant EGFR mutated proteins () - Oct 24, 2020 - Abstract #SNO2020SNO_106;
P1
To study this further We generated two structurally different CARs by fusing the scFv of mAb806 to 4-1BB and Killer immunoglobulin like receptor (KIR) co-stimulatory domains...Unlike EGFR-specific cetuximab based CAR, EGFR-806CART cells did not kill EGFR wild type expressing fetal brain primary astrocytes and keratinocytes in vitro...The broad specificity of EGFR806 CART cells to amplified EGFR and its mutant variants gives us the potential to clear various forms of EGFR. The enhanced anti-tumor efficacy by KIR based CAR in vivo setting provides us with additional therapeutic options.
- | SCRI-CARB7H3(s)x19 / Seattle Children's Hospital, SCRI-CARB7H3(s) / Cellevolve Bio
New P1 trial, CAR T-Cell Therapy, IO biomarker: STRIvE-02: B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov) - Jul 22, 2020
P1, N=68, Recruiting, Sponsor: Seattle Children's Hospital
- | HER2-Specific CAR T / Cellevolve Bio, Seattle Children's Therapeutics
Enrollment change, CAR T-Cell Therapy, IO biomarker: HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors (clinicaltrials.gov) - Apr 6, 2020
P1, N=48, Recruiting, Sponsor: Seattle Children's Hospital
The enhanced anti-tumor efficacy by KIR based CAR in vivo setting provides us with additional therapeutic options. N=36 --> 48
- | SCRI-CARB7H3(s) / Cellevolve Bio, Seattle Children's Therapeutics
New P1 trial, CAR T-Cell Therapy, IO biomarker: BrainChild-03: Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors (clinicaltrials.gov) - Dec 3, 2019
P1, N=70, Recruiting, Sponsor: Seattle Children's Hospital
- | EGFR806-specific CAR T-cell therapy / Cellevolve Bio, Seattle Children's Therapeutics
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: STRIvE-01: EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov) - Oct 15, 2019
P1, N=36, Recruiting, Sponsor: Seattle Children's Hospital
N=36 --> 48 Trial completion date: Oct 2036 --> Jun 2036 | Trial primary completion date: Oct 2021 --> Jun 2021
- | EGFR806-specific CAR T-cell therapy / Cellevolve Bio, Seattle Children's Therapeutics
Trial initiation date, CAR T-Cell Therapy: STRIvE-01: EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov) - Apr 5, 2019
P1, N=36, Recruiting, Sponsor: Seattle Children's Hospital
Trial completion date: Oct 2036 --> Jun 2036 | Trial primary completion date: Oct 2021 --> Jun 2021 Initiation date: Oct 2018 --> Oct 2019
- | EGFR806-specific CAR T-cell therapy / Cellevolve Bio, Seattle Children's Therapeutics
Enrollment open, CAR T-Cell Therapy, IO biomarker: EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors (clinicaltrials.gov) - Dec 19, 2018
P1, N=36, Recruiting, Sponsor: Seattle Children's Hospital
Initiation date: Oct 2018 --> Oct 2019 Not yet recruiting --> Recruiting
- | EGFR806-specific CAR T-cell therapy / Cellevolve Bio, Seattle Children's Therapeutics
New P1 trial, CAR T-Cell Therapy, IO biomarker: EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors (clinicaltrials.gov) - Aug 19, 2018
P1, N=36, Not yet recruiting, Sponsor: Seattle Children's Hospital
- | EGFR806-specific CAR T-cell therapy / Cellevolve Bio, Seattle Children's Therapeutics
New P1 trial, CAR T-Cell Therapy: STRIvE-01: EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov) - Aug 7, 2018
P1, N=36, Recruiting, Sponsor: Seattle Children's Hospital
- | HER2-Specific CAR T / Cellevolve Bio, Seattle Children's Therapeutics
Enrollment open, Trial completion date, Trial primary completion date, CAR T-Cell Therapy, IO biomarker: HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors (clinicaltrials.gov) - Jun 20, 2018
P1, N=36, Recruiting, Sponsor: Seattle Children's Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Apr 2035 --> Jun 2036 | Trial primary completion date: Apr 2020 --> Jun 2021
- | HER2-Specific CAR T / Cellevolve Bio, Seattle Children's Therapeutics
New P1 trial, CAR T-Cell Therapy, IO biomarker: HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors (clinicaltrials.gov) - Apr 17, 2018
P1, N=36, Not yet recruiting, Sponsor: Seattle Children's Hospital